P. F. Chinnery and D. M. Turnbull, Epidemiology and treatment of mitochondrial disorders, Am J Med Genet, vol.106, pp.94-101, 2001.

M. Zeviani and D. Donato, Brain, vol.127, pp.2153-2172, 2004.

S. Dimauro and M. Mancuso, Mitochondrial diseases: therapeutic approaches, Biosci Rep, vol.27, pp.125-137, 2007.

B. H. Robinson, Human cytochrome oxidase deficiency, Pediatr Res, vol.48, pp.581-585, 2000.

D. P. Kelly and R. C. Scarpulla, Transcriptional regulatory circuits controlling mitochondrial biogenesis and function, Genes Dev, vol.18, pp.357-368, 2004.

R. C. Scarpulla, Nuclear control of respiratory gene expression in mammalian cells, J Cell Biochem, vol.97, pp.673-683, 2006.

B. N. Finck and D. P. Kelly, PGC-1 coactivators: inducible regulators of energy metabolism in health and disease, J Clin Invest, vol.116, pp.615-622, 2006.

J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions, Prog Lipid Res, vol.45, pp.120-159, 2006.

C. H. Lee, P. Olson, and R. M. Evans, Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors, Endocrinology, vol.144, pp.2201-2207, 2003.

S. Luquet, J. Lopez-soriano, D. Holst, A. Fredenrich, J. Melki et al., Peroxisome proliferator-activated receptor ? controls muscle development and oxidative capability, FASEB J, vol.17, pp.2299-2301, 2003.

Y. X. Wang, C. L. Zhang, R. T. Yu, H. K. Cho, M. C. Nelson et al., Regulation of muscle fiber type and running endurance by PPAR?, PLoS Biol, vol.2, p.294, 2004.

E. Hondares, I. Pineda-torra, R. Iglesias, B. Staels, F. Villarroya et al., PPAR?, but not PPAR?, activates PGC-1? gene transcription in muscle, Biochem Biophys Res Commun, vol.354, pp.1021-1027, 2007.

P. Benit, R. Beugnot, D. Chretien, I. Giurgea, D. Lonlay-debeney et al., Mutant NDUFV2 subunit of mitochondrial complex I causes early onset hypertrophic cardiomyopathy and encephalopathy, Hum Mutat, vol.21, pp.582-586, 2003.

P. Benit, D. Chretien, N. Kadhom, P. De-lonlay-debeney, V. Cormier-daire et al., Large-scale deletion and point mutations of the nuclear NDUFV1 and NDUFS1 genes in mitochondrial complex I deficiency, Am J Hum Genet, vol.68, pp.1344-1352, 2001.

P. Benit, A. Slama, F. Cartault, I. Giurgea, D. Chretien et al., Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome, J Med Genet, vol.41, pp.14-17, 2004.

P. De-lonlay, I. Valnot, A. Barrientos, M. Gorbatyuk, A. Tzagoloff et al., A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure, Nat Genet, vol.29, pp.57-60, 2001.

A. Rotig, S. Lebon, E. Zinovieva, J. Mollet, E. Sarzi et al., Molecular diagnostics of mitochondrial disorders, Biochim Biophys Acta, vol.1659, pp.129-135, 2004.

I. Valnot, V. Kleist-retzow, J. C. Barrientos, A. Gorbatyuk, M. Taanman et al., A mutation in the human heme A:farnesyltransferase gene (COX10) causes cytochrome c oxidase deficiency, Hum Mol Genet, vol.9, pp.1245-1249, 2000.

V. Kleist-retzow, J. C. Yao, J. Taanman, J. W. Chantrel, K. Chretien et al., Mutations in SURF1 are not specifically associated with Leigh syndrome, J Med Genet, vol.38, pp.109-113, 2001.

S. Sacconi, L. Salviati, C. M. Sue, S. Shanske, M. M. Davidson et al., Mutation screening in patients with isolated cytochrome c oxidase deficiency, Pediatr Res, vol.53, pp.224-230, 2003.

E. A. Shoubridge, Cytochrome c oxidase deficiency, Am J Med Genet, vol.106, pp.46-52, 2001.

F. Djouadi, F. Aubey, D. Schlemmer, and J. Bastin, Peroxisome proliferator activated receptor ? (PPAR?) agonist but not PPAR? corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells, J Clin Endocrinol Metab, vol.90, pp.1791-1797, 2005.

D. M. Muoio, P. S. Maclean, D. B. Lang, S. Li, J. A. Houmard et al., Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) ? knock-out mice. Evidence for compensatory regulation by PPAR?, J Biol Chem, vol.277, pp.26089-26097, 2002.

A. Barrientos, In vivo and in organello assessment of OXPHOS activities, Methods, vol.26, pp.307-316, 2002.

D. Chretien, P. Benit, M. Chol, S. Lebon, A. Rotig et al., Assay of mitochondrial respiratory chain complex I in human lymphocytes and cultured skin fibroblasts, Biochem Biophys Res Commun, vol.301, pp.222-224, 2003.

P. Rustin, D. Chretien, T. Bourgeron, B. Gerard, A. Rotig et al., Munnich A 1994 Biochemical and molecular investigations in respiratory chain deficiencies, Clin Chim Acta, vol.228, pp.35-51

W. S. Kunz, A. Kudin, S. Vielhaber, C. E. Elger, G. Attardi et al., Flux control of cytochrome c oxidase in human skeletal muscle, J Biol Chem, vol.275, pp.27741-27745, 2000.

G. Villani, M. Greco, S. Papa, and G. Attardi, Low reserve of cytochrome c oxidase capacity in vivo in the respiratory chain of a variety of human cell types, J Biol Chem, vol.273, pp.31829-31836, 1998.

G. Villani and G. Attardi, In vivo control of respiration by cytochrome c oxidase in human cells, Free Radic Biol Med, vol.29, pp.202-210, 2000.

A. V. Kuznetsov, K. Winkler, E. Kirches, H. Lins, H. Feistner et al., Application of inhibitor titrations for the detection of oxidative phosphorylation defects in saponin-skinned muscle fibers of patients with mitochondrial diseases, Biochim Biophys Acta, vol.1360, pp.142-150, 1997.

D. A. Varlamov, A. P. Kudin, S. Vielhaber, R. Schroder, R. Sassen et al., Metabolic consequences of a novel missense mutation of the mtDNA CO I gene, Hum Mol Genet, vol.11, pp.1797-1805, 2002.

P. Chinnery, K. Majamaa, D. Turnbull, and D. Thorburn, Treatment for mitochondrial disorders, Cochrane Database Syst Rev, p.4426, 2006.

S. L. Williams, I. Valnot, P. Rustin, and J. W. Taanman, Cytochrome c oxidase subassemblies in fibroblast cultures from patients carrying mutations in COX10, SCO1, or SURF1, J Biol Chem, vol.279, pp.7462-7469, 2004.

M. Schuler, F. Ali, C. Chambon, D. Duteil, J. M. Bornert et al., PGC1? expression is controlled in skeletal muscles by PPAR?, whose ablation results in fiber-type switching, obesity, and type 2 diabetes, Cell Metab, vol.4, pp.407-414, 2006.

Z. Wu, P. Puigserver, U. Andersson, C. Zhang, G. Adelmant et al., Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1, Cell, vol.98, pp.115-124, 1999.

A. Tenenbaum, M. Motro, and E. Z. Fisman, Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons, Cardiovasc Diabetol, vol.4, p.14, 2005.

G. D. Barish, V. A. Narkar, and R. M. Evans, PPAR?: a dagger in the heart of the metabolic syndrome, J Clin Invest, vol.116, pp.590-597, 2006.

V. K. Mootha, C. M. Lindgren, K. F. Eriksson, A. Subramanian, S. Sihag et al., Groop LC 2003 PGC-1?-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes, vol.34, pp.267-273

M. E. Patti, A. J. Butte, S. Crunkhorn, K. Cusi, R. Berria et al., Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1, Proc Natl Acad Sci, vol.100, pp.8466-8471, 2003.